Eurofins Scientific (ERF) Q3 2025 earnings summary

Executive summary

• Reported revenues for the first nine months of 2025 reached €5,415m, up 5.3% year-over-year, driven by 4.0% organic growth and acquisitions, despite FX headwinds and one fewer public working day.

• Progress on the five-year plan for a world-class laboratory network is on track, with new labs nearing completion in key locations and 8 new start-up labs and 22 blood collection points opened.

• Digitalization initiatives and productivity improvements are advancing, aiming for completion by 2027 to enhance efficiency and reduce costs.

• 31 acquisitions were closed in 9M 2025, expanding technological capabilities and global footprint, including SYNLAB's clinical diagnostics operations in Spain.

• CEO highlighted continued innovation, margin expansion, and strong financial execution, with margin improvements expected to outpace revenue growth.

Financial highlights

• Organic growth guidance is mid-single digit, with 4.0% organic growth for 9M 2025 and 4.2% for Q3 2025, adjusted for working days.

• Acquired revenues for the year are approximately €210m on a full-year basis, with 31 acquisitions contributing over €250m in FY 2024 pro-forma revenues.

• Adjusted EBITDA margin for FY 2024 was 22.3%, with further improvement expected in FY 2025.

• FX headwinds, mainly from the US Dollar/Euro, are estimated at -1.5% to -1.6% on revenue, with a minor margin impact of about 0.2% on a full-year basis.

• Start-ups contributed 0.6% to organic growth in 9M 2025.

Outlook and guidance

• FY 2025 and 2027 objectives are confirmed, with expectations of strong Q4 performance as base effects from large studies and pricing reductions fade.

• Margin improvements are expected to continue, supported by digitalization and network expansion, even with FX and acquisition dilution.

• Free cash flow and cash conversion are set to increase as major building investments wind down.

• If current US Dollar/Euro rates persist, a -1.6% headwind to FY 2025 reported revenue and ~20bps lower EBITDA margin is expected.